Verve Therapeutics (NASDAQ:VERV) Receives "Buy" Rating from HC Wainwright

Verve Therapeutics (NASDAQ:VERV - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 187.36% from the company's previous close.

A number of other equities analysts have also commented on VERV. William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $25.50.

Verve Therapeutics Price Performance

Shares of NASDAQ:VERV traded down $0.06 during trading on Tuesday, reaching $5.22. 585,375 shares of the stock were exchanged, compared to its average volume of 1,450,618. Verve Therapeutics has a 1-year low of $4.31 and a 1-year high of $13.24. The firm has a market cap of $463.52 million, a price-to-earnings ratio of -2.12 and a beta of 1.77. The stock has a fifty day moving average of $6.94 and a two-hundred day moving average of $6.08.

Remove Ads

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $13.08 million for the quarter, compared to analysts' expectations of $3.94 million. Sell-side analysts forecast that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VERV. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after buying an additional 3,964 shares during the period. IFP Advisors Inc boosted its holdings in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after purchasing an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Verve Therapeutics during the 4th quarter valued at approximately $50,000. Erste Asset Management GmbH bought a new stake in Verve Therapeutics in the third quarter worth $56,000. Finally, Impact Partnership Wealth LLC bought a new stake in shares of Verve Therapeutics in the 4th quarter worth about $70,000. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.